Switch-It

Switch Therapeutics is a biotechnology company focused on developing a novel class of RNA-based medicines using its proprietary Conditionally Activated siRNA (CASi) platform. The CASi technology integrates the efficient gene knockdown of siRNA with the ability to activate only in specific cell types, potentially improving the safety and precision of RNA interference therapies. The company's primary focus is on treating devastating central nervous system (CNS) diseases, where traditional delivery and targeting have been challenging. By utilizing a unique structural approach that allows for self-delivery and cell-selective activation, Switch aims to expand the reach of RNAi to previously undruggable neurological targets. The company is currently advancing its lead programs toward clinical development, with a focus on neurodegenerative conditions.